Cognitive effects of atypical antipsychotic drugs in first-episode drug-naïve schizophrenic patients

Cognitive impairment is a core feature of schizophrenia. The present randomized open study enrolled antipsychotic-naïve patients who were experiencing their first episode of schizophrenia. After baseline neurocognitive tests and clinical assessment, subjects were randomly assigned to olanzapine, risperidone and aripiprazole treatment groups. A battery of neurocognitive tests showed that risperidone produced cognitive benefits in all five cognitive domains, including verbal learning and memory, visual learning and memory, working memory, processing speed, and selective attention; olanzapine improved processing speed and selective attention; and aripiprazole improved visual learning and memory, and working memory. However, the three atypical antipsychotic drugs failed to reveal any significant differences in the composite cognitive scores at the study endpoint. In addition, the three drugs all significantly improved clinical measures without significant differences between the drugs after 6 months. These results suggest that the atypical antipsychotics, olanzapine, risperidone and aripiprazole may improve specific cognitive domains with similar global clinical efficacy. In clinical practice, it may be feasible to choose corresponding atypical antipsychotics according to impaired cognitive domains.

[1]  Ralph H. B. Benedict,et al.  Hopkins Verbal Learning Test--Revised , 2013 .

[2]  Norio Sugawara,et al.  Effect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patients , 2012, Journal of psychopharmacology.

[3]  R. Yoshimura,et al.  The cognitive profile of aripiprazole differs from that of other atypical antipsychotics in schizophrenia patients. , 2012, Journal of psychiatric research.

[4]  K. Krysta,et al.  Impact of olanzapine on cognitive functions in patients with schizophrenia during an observation period of six months. , 2011, Psychiatria Danubina.

[5]  A. Gade,et al.  Cognitive effects of six months of treatment with quetiapine in antipsychotic-naïve first-episode schizophrenia , 2011, Psychiatry Research.

[6]  C. Arango,et al.  Cognitive efficacy of quetiapine and olanzapine in early-onset first-episode psychosis. , 2011, Schizophrenia bulletin.

[7]  H. Möller,et al.  Neurocognition and its influencing factors in the treatment of schizophrenia—effects of aripiprazole, olanzapine, quetiapine and risperidone , 2010, Human psychopharmacology.

[8]  H. Möller,et al.  Effect of aripiprazole on cognition in the treatment of patients with schizophrenia. , 2010, Pharmacopsychiatry.

[9]  R. Kahn,et al.  Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). , 2009, The American journal of psychiatry.

[10]  V. Peralta,et al.  Cognitive effectiveness of olanzapine and risperidone in first-episode psychosis , 2009, British Journal of Psychiatry.

[11]  J. Vázquez-Barquero,et al.  Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison. , 2009, The Journal of clinical psychiatry.

[12]  S. Galderisi,et al.  Cognitive-enhancing effects of aripiprazole: a case report , 2008, Clinical practice and epidemiology in mental health : CP & EMH.

[13]  Todd Lencz,et al.  Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? , 2007, Archives of general psychiatry.

[14]  J. Lieberman,et al.  Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. , 2007, The American journal of psychiatry.

[15]  Michael F. Green,et al.  Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. , 2007, Archives of general psychiatry.

[16]  D. Zald,et al.  A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: Dose effects and comparison to practice effects , 2007, Schizophrenia Research.

[17]  Philip D. Harvey,et al.  Negative symptoms and cognitive deficits: what is the nature of their relationship? , 2006, Schizophrenia bulletin.

[18]  Jeffrey A. Lieberman,et al.  Long-Term Neurocognitive Effects of Olanzapine or Low-Dose Haloperidol in First-Episode Psychosis , 2006, Biological Psychiatry.

[19]  J. Gold,et al.  One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia , 2006, Schizophrenia Research.

[20]  Philip D. Harvey,et al.  Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. , 2005, The American journal of psychiatry.

[21]  Herbert Y Meltzer,et al.  A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. , 2005, The international journal of neuropsychopharmacology.

[22]  Michael F. Green,et al.  Identification of separable cognitive factors in schizophrenia , 2004, Schizophrenia Research.

[23]  A. Malla,et al.  A comparison of two novel antipsychotics in first episode non-affective psychosis: one-year outcome on symptoms, motor side effects and cognition , 2004, Psychiatry Research.

[24]  J. Gold.  Cognitive deficits as treatment targets in schizophrenia , 2004, Schizophrenia Research.

[25]  Jin Dai,et al.  Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. , 2004, European journal of pharmacology.

[26]  J. Lieberman,et al.  Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. , 2004, The American journal of psychiatry.

[27]  A Labelle,et al.  Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. , 2000, Archives of general psychiatry.

[28]  David Wechsler,et al.  Wechsler Memory scale. , 2005 .

[29]  J. Lieberman,et al.  The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. , 1999, Schizophrenia bulletin.

[30]  H. Meltzer,et al.  The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. , 1999, Schizophrenia bulletin.

[31]  S. Kay,et al.  The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.